Related Experiment Video
Updated: Jul 17, 2025
Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity
Published on: December 7, 2019
Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC
Jianxin Wang1, Tengyi Zhang2, Pan Li1
1Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Skip Viragh Pancreatic Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; The Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA; Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Researchers identified a specific T-cell target, LAMC2203-211, for pancreatic ductal adenocarcinoma (PDAC) immunotherapy. This LAMC2-targeting T-cell therapy shows potent anti-PDAC effects in vitro and in vivo, offering a promising strategy for many patients.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Tumor antigens are vital for T-cell therapies to eliminate cancer.
- Identifying specific T-cell epitopes in pancreatic ductal adenocarcinoma (PDAC) has been difficult.
- Previous mass spectrometry (MS) analysis identified shared, cancer-associated epitopes in PDAC patients.
Purpose of the Study:
- To investigate the LAMC2203-211 epitope as a potential target for PDAC immunotherapy.
- To develop and evaluate a T-cell receptor (TCR)-based therapy targeting LAMC2 in PDAC.
Main Methods:
- Mass spectrometry (MS) was used to identify naturally occurring T-cell epitopes.
- T-cell receptors (TCRs) specific to LAMC2203-211 were cloned and engineered into T-cells.
- In vitro cytotoxicity assays and in vivo mouse models (subcutaneous and orthotopic) were used to assess therapeutic efficacy.
Main Results:
- Engineered T-cells expressing LAMC2203-211-specific TCRs demonstrated potent, specific cytotoxic effects against PDAC cells in vitro.
- Infusion of LAMC2-targeting T-cells suppressed tumor growth in mouse models, irrespective of HLA-A matching.
- Tumor suppression was dependent on the LAMC2 target.
Conclusions:
- A LAMC2-specific TCR-based T-cell therapy strategy has been developed for PDAC.
- This approach is potentially applicable to a broad range of PDAC patients.
- This study pioneers the use of MS for identifying natural CD8+ T-cell epitopes for PDAC immunotherapy.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
